

Adalimumab (anti-TNF- α)

Cat. No.:	HY-P9908A
CAS No.:	331731-18-1
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Adalimumab (anti-TNF- α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF- α).
In Vitro	Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF- α) than used in this study ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The elimination half-life ($t_{1/2}$) of Adalimumab (anti-TNF- α) is long (~20 days) ^[1] . The enriched fluorescent-labelled adalimumab (anti-TNF- α) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr ^{-/-} mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97.
- [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor- α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA